This article has been cited by other articles in PMC.
The Full Text of this article is available as a PDF (87K).
These references are in PubMed. This may not be the complete list of references from this article.
Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol. 1999 Oct;28(4):248–254.[PubMed]
Cropp GJ. Effectiveness of bronchodilators in cystic fibrosis. Am J Med. 1996 Jan 29;100(1A):19S–29S.[PubMed]
van Haren EH, Lammers JW, Festen J, van Herwaarden CL. Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adult patients with cystic fibrosis. Eur Respir J. 1992 Oct;5(9):1083–1088.[PubMed]
Macfarlane PI, Heaf D. Changes in airflow obstruction and oxygen saturation in response to exercise and bronchodilators in cystic fibrosis. Pediatr Pulmonol. 1990;8(1):4–11.[PubMed]
Wood RE, Wanner A, Hirsch J, Farrell PM. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. Am Rev Respir Dis. 1975 Jun;111(6):733–738.[PubMed]
Mortensen J, Hansen A, Falk M, Nielsen IK, Groth S. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest. 1993 Mar;103(3):805–811.[PubMed]
Hordvik NL, König P, Morris D, Kreutz C, Barbero GJ. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis. 1985 Jun;131(6):889–893.[PubMed]
Eber E, Oberwaldner B, Zach MS. Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathomimetics. Pediatr Pulmonol. 1988;4(4):205–212.[PubMed]
Hellinckx J, De Boeck K, Demedts M. No paradoxical bronchodilator response with forced oscillation technique in children with cystic fibrosis. Chest. 1998 Jan;113(1):55–59.[PubMed]
Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med. 1996 Jul;154(1):156–160.[PubMed]
Finnegan MJ, Hughes DV, Hodson ME. Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. Eur Respir J. 1992 Oct;5(9):1089–1091.[PubMed]
Bargon J, Viel K, Dauletbaev N, Wiewrodt R, Buhl R. Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Respir J. 1997 Oct;10(10):2307–2311.[PubMed]
Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol. 1999 Jan;27(1):43–53.[PubMed]
Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest. 1991 May;99(5):1088–1092.[PubMed]
König P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol. 1998 Jan;25(1):32–36.[PubMed]
Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press